8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
Apr 1, 2026·SEC
Material company update
Mar 30, 2026·SEC
Aprea Therapeutics, Inc.(APRE)Earnings, Financials & Key Ratios
APRE•NASDAQ
$0.79
Price updated Jun 27, 2026
AboutAprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.Show more
- Revenue$0-100.0%
- EBITDA-$13M+7.6%
- Net Income-$13M+2.8%
- EPS (Diluted)-1.93+17.9%
- ROE-79.37%-15.1%
APRE Price & Volume
Aprea Therapeutics, Inc. (APRE) stock price & volume — 10-year historical chart
Loading chart...
Clinical Pipeline Pivot Drives Severe Cash Depletion
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity and dilution
"Aprea Therapeutics has transitioned into a high-risk, pre-revenue clinical development model, effectively eliminating its legacy commercial revenue streams. The firm's reliance on R&D spending, which consistently consumes millions per quarter, creates an unsustainable burn profile that threatens long-term viability. Investors should monitor the company's precarious $14.6 million cash position, which necessitates either a strategic partnership or highly dilutive equity financing to sustain its ATR inhibitor pipeline."
Verdict Logic
the company's rapid depletion of cash reserves to $14.6 million against recurring quarterly operating losses suggests an imminent risk of significant shareholder dilution.
APRE Growth Metrics
Aprea Therapeutics, Inc. (APRE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-90.8%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM15.1%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM26.16%
Return on Capital
10 Years-86.44%
5 Years-115.2%
3 Years-73.47%
Last Year-78.34%
APRE Recent Earnings
Aprea Therapeutics, Inc. (APRE) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 3/12 qtrs (50%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.22+4.3%
$0.23
Rev
$281,000
—
Q2 2026
Mar 16, 2026Metric
Actual
Est
EPS
$0.32+15.8%
$0.38
Rev
$3,337+0.0%
$3,337
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.47-327.3%
$0.11
Rev
$1,848
—
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.53+31.2%
$0.77
Rev
$118,111
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.22vs $0.23+4.3% | $281,000 |
| Q2 2026 | Mar 16, 2026 | $0.32vs $0.38+15.8% | $3,337vs $3,337+0.0% |
| Q4 2025 | Nov 12, 2025 | $0.47vs $0.11-327.3% | $1,848 |
| Q3 2025 | Aug 12, 2025 | $0.53vs $0.77+31.2% | $118,111 |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Aprea Therapeutics, Inc. (APRE)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.79 | $5.13M | -0.41 | -100% | — | -79.37% | — | |
| $38.85 | $7.98B | -14.03 | — | — | -68.16% | — | |
| $108.12 | $8.83B | -29.30 | -16.72% | -612.17% | -25.02% | — | |
| $3.03 | $126.18M | -891.18 | 10.37% | 52.16% | — | — | |
| $4.70 | $190.82M | 3.85 | 36.55% | -19.55% | -3.39% | — | |
| $3.43 | $619.52M | -2.54 | 55.28% | -4917.55% | -188.82% | — |
Compare APRE vs Peers
Aprea Therapeutics, Inc. (APRE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
APRE SEC Filings & Documents
Aprea Therapeutics, Inc. (APRE) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when APRE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
APRE Frequently Asked Questions
Aprea Therapeutics, Inc. (APRE) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Aprea Therapeutics, Inc.'s revenue?
Aprea Therapeutics, Inc. (APRE) reported $0.1M in revenue for fiscal year 2025.
How fast is Aprea Therapeutics, Inc. growing?
Aprea Therapeutics, Inc. (APRE) saw revenue decline by 100.0% over the past year.
Is APRE profitable?
Aprea Therapeutics, Inc. (APRE) reported a net loss of $12.0M for fiscal year 2025.
Dividend & Returns
What is APRE's return on equity?
Aprea Therapeutics, Inc. (APRE) has a return on equity (ROE) of -79.4%. Negative ROE indicates the company is unprofitable.
What is Aprea Therapeutics, Inc.'s free cash flow?
Aprea Therapeutics, Inc. (APRE) had negative free cash flow of $12.2M in fiscal year 2025, likely due to heavy capital investments.